Ginkgo biloba extract EGb 761® in children with ADHD: Preliminary findings of an open multilevel dose-finding study

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 42, Issue 5, 2014, Pages 337-347

  Uebel Von Sandersleben, Henrik ^a   Rothenberger, Aribert ^a   Albrecht, Björn ^a   Rothenberger, L Geza ^b   Klement, Stephan ^c   Bock, Nathalie ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

ADHD; Complementary and alternative medicine; Electrophysiology; Ginkgo biloba; Safety and efficiency

Indexed keywords

GINKGO BILOBA EXTRACT; GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN ELECTROPHYSIOLOGY; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTINGENT NEGATIVE VARIATION; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DSM-IV; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PILOT STUDY; QUALITY OF LIFE; SIDE EFFECT RATING SCALE; TASK PERFORMANCE; THROMBIN TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADHS; ADOLESCENT; ALTERNATIVE BEHANDLUNGSMÖGLICHKEITEN; ATTENTION; BRAIN; BRAIN MAPPING; CLINICAL TRIAL; COMPLEMENTARY AND ALTERNATIVE MEDICINE; DRUG ADMINISTRATION; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; ELEKTROPHYSIOLOGIE; EVOKED RESPONSE; GERMANY; GINKGO BILOBA; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SAFETY AND EFFICIENCY; SICHERHEIT; SIGNAL PROCESSING; WIRKSAMKEIT;

ADHD; ADHS; ALTERNATIVE BEHANDLUNGSMÖGLICHKEITEN; COMPLEMENTARY AND ALTERNATIVE MEDICINE; ELECTROPHYSIOLOGY; ELEKTROPHYSIOLOGIE; GINKGO BILOBA; SAFETY AND EFFICIENCY; SICHERHEIT; WIRKSAMKEIT;

ADOLESCENT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; BRAIN MAPPING; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; GERMANY; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PLANT EXTRACTS; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 84906973824     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917/a000309     Document Type: Article

References (38)

1. Albrecht, B., Brandeis, D., Uebel, H., Valko, L., Heinrich, H., Drechsler, R., . . . Banaschewski, T. (2012). Familiality of neural preparation and response control in childhood attention deficit- hyperactivity disorder. Psychological Medicine, 43, 1997-2011.
2. Banaschewski, T., Brandeis, D., Heinrich, H., Albrecht, B., Brunner, E., & Rothenberger, A. (2003). Association of ADHD and conduct disorder: Brain electrical evidence for the existence of a distinct subtype. Journal of Child Psychology and Psychiatry and Allied Disciplines, 44, 356-376.
3. Banaschewski, T., Coghill, D., Santosh, P., Zuddas, A., Asherson, P., Buitelaar, J., . . . Taylor, E. (2006). Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. European Child and Adolescent Psychiatry, 15, 476-495.
4. Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, CD003120.
5. Cala, S., Crismon, M.L., & Baumgartner, J. (2003). A survey of herbal use in children with attention-deficit-hyperactivity disorder or depression. Pharmacotherapy, 23, 222-230.
6. Dimpfel, W., Kler, A., Kriesl, E., Lehnfeld, R., & Keplinger- Dimpfel, I. K. (2006). Neurophysiological characterization of a functionally active drink containing extracts of ginkgo and ginseng by source density analysis of the human EEG. Nutritional Neuroscience, 9, 213-224.
7. Doehnert, M., Brandeis, D., Imhof, K., Drechsler, R., & Steinhausen, H. C. (2010). Mapping attention-deficit/hyperactivity disorder from childhood to adolescence: No neurophysiologic evidence for a developmental lag of attention but some for inhibition. Biological Psychiatry, 67, 608-616.
8. Doehnert, M., Brandeis, D., Straub, M., Steinhausen, H. C., & Drechsler, R. (2008). Slow cortical potential neurofeedback in attention deficit hyperactivity disorder: Is there neurophysiological evidence for specific effects? Journal of Neural Transmission, 115, 1445-1456.
9. Döpfner, M., Gortz-Dorten, A., Breuer, D., & Rothenberger, A. (2011). An observational study of once-daily modified-release methylphenidate in ADHD: Effectiveness on symptoms and impairment, and safety. European Child and Adolescent Psychiatry, 20(Suppl 2), 243-255.
10. Döpfner, M., & Lehmkuhl, G. (2000). Diagnostik-System für Psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV (DISYPS-KJ) (2nd ed.). Bern: Huber.
11. Faul, F., Erdfelder, E., Lang, A. G., & Buchner, A. (2007). G∗Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39, 175-191.
12. Feucht, C., & Patel, D. R. (2011). Herbal medicines in pediatric neuropsychiatry. Pediatric Clinics of North America, 58, 33-54.
13. Gevensleben, H., Rothenberger, A., Moll, G. H., & Heinrich, H. (2012). Neurofeedback in children with ADHD: Validation and challenges. Expert Review of Neurotherapeutics, 12, 447-460.
14. Goodman, R. (1997). The Strengths and Difficulties Questionnaire: A research note. Journal of Child Psychology and Psychiatry and Allied Disciplines, 38, 581-586.
15. Gortz-Dorten, A., & Döpfner, M. (2009). Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörungen von Kindern und Jugendlichen im Elternurteil - Eine Analyse an einer Feldstichprobe mit dem Diagnostik-System DISYPS - II [Attention deficit/hyperactive disorders in children and adolescents as assessed by parents]. Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, 37, 183-194.
16. Gratton, G., Coles, M. G., & Donchin, E. (1983). A new method for off-line removal of ocular artifact. Electroencephalography and Clinical Neurophysiology, 55, 468-484.
17. Heinrich, H., Gevensleben, H., Freisleder, F. J., Moll, G. H., & Rothenberger, A. (2004). Training of slow cortical potentials in attention-deficit/hyperactivity disorder: Evidence for positive behavioral and neurophysiological effects. Biological Psychiatry, 55, 772-775.
18. Herrschaft, H., Nacu, A., Likhachev, S., Sholomov, I., Hoerr, R., & Schlaefke, S. (2012). Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: A randomised, placebo- controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. Journal of Psychiatric Research, 46, 716-723.
19. Itil, T. M., Eralp, E., Tsambis, E., Itil, K. Z., & Stein, U. (1996). Central nervous system effects of ginkgo biloba, a plant extract. American Journal of Therapeutics, 3, 63-73.
20. Jacobsson, I., Jonsson, A. K., Gerden, B., & Hagg, S. (2009). Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiology Drug Safety, 18, 1039-1047.
21. Lingjaerde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 334 (Suppl), 1-100.
22. Lorenc, A., Ilan-Clarke, Y., Robinson, N., & Blair, M. (2009). How parents choose to use CAM: a systematic review of theoretical models. BMC Complement Altern Med, 9, 9.
23. Lyon, M. R., Cline, J. C., Totosy de Zepetnek, J., Shan, J. J., Pang, P., & Benishin, C. (2001). Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attentiondeficit hyperactivity disorder: A pilot study. Journal of Psychiatry and Neuroscience, 26, 221-228.
24. McLoughlin, G., Albrecht, B., Banaschewski, T., Rothenberger, A., Brandeis, D., Asherson, P., & Kuntsi, J. (2010). Electrophysiological evidence for abnormal preparatory states and inhibitory processing in adult ADHD. Behavioral and Brain Functions, 6, 66.
25. Nathan, P. (2000). Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology? Medical Hypotheses, 55, 491-493.
26. Niederhofer, H. (2010). Ginkgo biloba treating patients with attention- deficit disorder. Phytotherapy Research, 24, 26-27.
27. Ravens-Sieberer, U., & Bullinger, M. (1998). Assessing healthrelated quality of life in chronically ill children with the German KINDL: First psychometric and content analytical results. Quality of Life Research, 7, 399-407.
28. Ravens-Sieberer, U., Morfeld, M., Stein, R. E., Jessop, D. J., Bullinger, M., & Thyen, U. (2001). Der Familien-Belastungs-Fragebogen (FaBel-Fragebogen) - Testung und Validierung der deutschen Version der "Impact on Family Scale" bei Familien mit behinderten Kindern [The testing and validation of the German version of the Impact on Family Scale in families with children with disabilities]. Psychotherapie, Psychosomatik, Medizinische Psychologie, 51, 384-393.
29. Rigney, U., Kimber, S., & Hindmarch, I. (1999). The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytotherapy Research, 13, 408-415.
30. Salehi, B., Imani, R., Mohammadi, M.R., Fallah, J., Mohammadi, M., Ghanizadeh, A., . . . Akhondzadeh, S. (2010). Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: A double-blind, randomized controlled trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 76-80.
31. Sarris, J., Kean, J., Schweitzer, I., & Lake, J. (2011). Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): A systematic review of the evidence. Complementary Therapies in Medicine, 19, 216-227.
32. Semlitsch, H.V., Anderer, P., Saletu, B., Binder, G. A., & Decker, K. A. (1995). Cognitive psychophysiology in nootropic drug research: Effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment. Pharmacopsychiatry, 28, 134-142.
33. Soh, N. L., & Walter, G. (2008). Complementary medicine for psychiatric disorders in children and adolescents. Current Opinion in Psychiatry, 21, 350-355.
34. Subhan, Z., & Hindmarch, I. (1984). The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. International Journal of Clinical Pharmacology Research, 4, 89-93.
35. Valko, L., Doehnert, M., Müller, U. C., Schneider, G., Albrecht, B., Drechsler, . . . Brandeis, D. (2009). Differences in neurophysiological markers of inhibitory and temporal processing deficits in children and adults with ADHD. Journal of Psychophysiology, 23, 235-246.
36. Wehmeier, P.M., Schacht, A., Dittmann, R.W., Helsberg, K., Schneider-Fresenius, C., Lehmann, M., . . . Ravens-Sieberer, U. (2011). Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double- blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. Quality of Life Research, 20, 691-702.
37. Weinmann, S., Roll, S., Schwarzbach, C., Vauth, C., & Willich, S. N. (2010). Effects of Ginkgo biloba in dementia: Systematic review and meta-analysis. BMC Geriatrics, 10, 14.
38. Woerner, W., Becker, A., & Rothenberger, A. (2004). Normative data and scale properties of the German parent SDQ. European Child and Adolescent Psychiatry, 13(Suppl 2), II3-10.